Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company, recently announced a reduction in force (RIF) as part of its strategic initiative to prioritize opportunities in rice, biofragrance products, and sustainable ingredients. This move is aimed at optimizing the company’s Trait Machine gene editing processes and advancing its weed management traits in rice, while continuing […]
Category: gene editing
Safety Concerns Arise from Intellia’s CRISPR Drug Filing
In the high-stakes arena of biopharmaceutical innovation, Intellia Therapeutics’ recent disclosure process offers valuable insights into the intricate dance of transparency, risk management, and market impact. The company has been thrust into the limelight following safety concerns about its groundbreaking CRISPR drug, leading to an intense, high-profile disclosure process that rattled both investors and the […]
CRISPR Baby Tech Investment by Crypto Billionaire
“Crypto billionaire Brian Armstrong is on the brink of making a significant investment in the controversial and groundbreaking field of CRISPR baby technology. This field, focused on the genetic editing of embryos, could be a game-changer in the realm of genetic modification. Specifically, Armstrong is interested in funding a US-based startup that aims to pioneer […]
